AF
RLAY icon

Advisornet Financial’s Relay Therapeutics RLAY Stock Holding History

Advisornet Financial’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3
Closed -$38 – 2397
2023
Q2 		$38 Hold
3
– – ﹤0.01% 2323
2023
Q1 		$49 Buy
+3
New +$54 ﹤0.01% 2356

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Advisornet Financial's RLAY Position: Q3 2023 in Review

Advisornet Financial sold out of Relay Therapeutics (RLAY) in Q3 2023, closing a stake of 3 shares — an estimated $38 sold.

Advisornet Financial first reported a position in RLAY in Q1 2023 and held it in 2 quarters. The position peaked at $49 in Q1 2023. 172 funds tracked by Wall St. Rank hold RLAY as of Q3 2023.

  • Advisornet Financial reported no remaining Relay Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Advisornet Financial sold 3 Relay Therapeutics shares in Q3 2023, an estimated $38.
  • Advisornet Financial first reported a position in Relay Therapeutics in Q1 2023 and held it in 2 quarters.
  • Advisornet Financial's Relay Therapeutics position peaked at $49 in Q1 2023.
  • 172 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2023.

Based on Advisornet Financial's 13F filing for Q3 2023, filed 12 Oct 2023.